Reforming EU and national orphan drug regulations to improve outcomes for patients with rare diseases.

Philip Kranz and colleagues argue that the alleged superior therapeutic benefit attributed to orphan drugs is often not supported by evidence from clinical trials and propose a reform of EU and national orphan drug regulations